NEW YORK, NY, August 22, 2011 --- Enzo Biochem Inc. (NYSE:ENZ) announced today that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.
The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D’Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.
Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary’s operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo’s presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.
“Enzo Life Sciences has developed numerous new products to meet the demands of these exciting growth markets and our investment in people—which we are announcing today—is a manifestation of our commitment to this exciting strategy. All four individuals are highly experienced, with technical expertise and impressive professional and commercial accomplishments; we are confident they will all make notable contributions to our Company’s growth,” says Barry Weiner, Enzo Biochem President.
Among the additions to Enzo Life Sciences’ offerings is a line of specific products and assays aimed at, among other areas, epigenetics, a burgeoning new approach to studying genetic variations in treatments and drug discoveries among large and small pharma.
Enzo Life Sciences’ emphasis is increasingly on developing platforms and products to meet the expanding needs of new and revolutionary pharmacological and genetic treatments, which often require extensive pre-clinical testing. In addition, these added capabilities will materially enhance the broader esoteric diagnostic direction at Enzo Clinical Labs, another subsidiary of Enzo Biochem, which is itself focused on greater national recognition and expanding the use of its higher value molecular testing capabilities.
The new Enzo Life Science appointments include:
Bruce Taillon, PhD, as head of global technology business development. He previously was associated with Roche Diagnostics’ 454 Life Sciences Division, where he was responsible for world-wide business development efforts centered around the company’s next generation nucleic acid sequencing platform and its potential use in diagnostic assays. He also has experience in leading R&D teams focused in the areas of genomics, proteomics and drug development.
John D’Errico, PhD, He will lead the Company’s commercial merchandising operations. Dr. D’Errico joins Enzo from VWR Scientific, where he managed that company’s life sciences product portfolio. He also brings extensive product management and M&A expertise from Harvard Biosciences, where he headed business development efforts at Genomic Solutions, a Life Science tools company.
Kara Cannon. Ms. Cannon was appointed head of Enzo Life Science’s global marketing, joining the Company after 10 years at Pall Corporation, where she held executive positions in the areas of diagnostics, biotechnology and biosciences. She has had extensive experience in the marketing and selling of innovative platforms for the diagnostics markets as well as the development and execution of strategic plans for the growth and sustainability of diagnostic-related businesses.
Paul Munger, PhD, Dr. Munger will lead Enzo Life Sciences’ Global Manufacturing Operations. He previously held an executive position at Pierce Chemical, now a division of Thermo Fisher, as well as a senior manufacturing management role at Transgenomic, Inc, where he was responsible for scaling up drug intermediate candidates that led to substantial cost reductions while raising quality and reducing turnaround time. Most recently Paul led the US-based manufacturing of regulated diagnostic kits for Idexx Labs.
About Enzo Biochem
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Pennsylvania and New Jersey. Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. In the course of the company’s research and development activities, Enzo has also developed a substantial portfolio of intellectual property asset with patent coverage across a number of key technologies.
Except for historical information, the matters discussed in this news release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
Contact:
For: Enzo Biochem, Inc.
Steven Anreder, 212-532-3232
or
Michael Wachs, CEOcast, Inc., 212-732-4300
